Ovarian Cancer
2,038
342
463
913
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
303 trials with published results (15%)
Research Maturity
913 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.7%
239 terminated out of 2038 trials
79.3%
-7.3% vs benchmark
8%
169 trials in Phase 3/4
33%
303 of 913 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 913 completed trials
Clinical Trials (2038)
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Prehabilitation in High-risk Oncologic Surgery
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients